TGFB1 and cancer: Taken together with previous studies, our findings reinforce the notion that inhibition of TGF-β1 might not affect the proliferation and viability of NSCLC effectively in monotherapy but may serve as a supportive agent for other anti-cancer drugs in combination therapy.